Solid had $206.1 million in cash, cash equivalents, and available-for-sale securities as of March 31, 2024, compared to $123.6 million as of December 31, 2023. The Company expects that its cash, cash equivalents, and available-for-sale securities as of March 31, 2024, will enable it to fund key strategic priorities into 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results
- Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
- Solid Biosciences receives Rae Pediatric Disease designation for SGT-003
- Palantir downgraded, CyberArk initiated: Wall Street’s top analyst calls
Questions or Comments about the article? Write to editor@tipranks.com